

## CLAIMS

What is claimed is:

1. A method to prevent, reduce or inhibit angiogenesis comprising the step of administering to a subject an effective amount of a lipoxin A<sub>4</sub> compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that angiogenesis is prevented, reduced or inhibited in the subject.
2. The method of claim 1, wherein the lipoxin A<sub>4</sub> compound is LXA<sub>4</sub> or 15-*R/S*-methyl, LXA<sub>4</sub>.
3. A method to prevent, reduce or inhibit angiogenesis comprising the step of administering to a subject an effective amount of a 15-*epi*-lipoxin A<sub>4</sub> compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that angiogenesis is prevented, reduced or inhibited in the subject.
4. The method of claim 3, wherein the 15-*epi*-lipoxin A<sub>4</sub> compound is 15-*epi*-16-(*para*-fluoro)-phenoxy-lipoxin A<sub>4</sub>.
5. A method for treating a subject for restenosis in a tissue wherein smooth muscle cell migration occurs following angioplasty, comprising administering to said subject a composition comprising an effective amount of a lipoxin A<sub>4</sub> compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that restenosis in a tissue wherein smooth muscle cell migration occurs following angioplasty is prevented, reduced, or inhibited.
6. The method of claim 5, wherein the lipoxin A<sub>4</sub> compound is LXA<sub>4</sub> or 15-*R/S*-methyl, LXA<sub>4</sub>.
7. A method for treating a subject for restenosis in a tissue wherein smooth muscle cell migration occurs following angioplasty, comprising administering to said subject a composition comprising an effective amount of a 15-*epi*-lipoxin A<sub>4</sub> compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that restenosis in a tissue wherein smooth muscle cell migration occurs following angioplasty is prevented, reduced, or inhibited.
8. The method of claim 7, wherein the 15-*epi*-lipoxin A<sub>4</sub> compound is 15-*epi*-16-(*para*-fluoro)-phenoxy-lipoxin A<sub>4</sub>.

9. A method to facilitate wound healing in a subject comprising the step of administering to the subject in need thereof, an effective amount of an LXB<sub>4</sub> compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that wound healing in the subject is facilitated.
- 5 10. The method of claim 9, wherein the LXB<sub>4</sub> compound is selected from the group consisting of 14-epi-LXB<sub>4</sub>, 15-epi-LXB<sub>4</sub> and 15-epi-LXB<sub>4</sub>-acetylenic.
11. A method to facilitate angiogenesis in a subject comprising the step of administering to the subject in need thereof, an effective amount of an LXB<sub>4</sub> compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that angiogenesis in  
10 the subject is facilitated.
12. The method of claim 11, wherein LXB<sub>4</sub> is excluded.
13. The method of claim 11, wherein the LXB<sub>4</sub> compound is selected from the group consisting of 14-epi-LXB<sub>4</sub>, 15-epi-LXB<sub>4</sub> and 15-epi-LXB<sub>4</sub>-acetylenic.
14. A method to facilitate neovascularization in a subject comprising the step of  
15 administering to the subject in need thereof, an effective amount of an LXB<sub>4</sub> compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that neovascularization in the subject is facilitated.
15. The method of claim 14, wherein LXB<sub>4</sub> is excluded.
16. The method of claim 14, wherein the LXB<sub>4</sub> compound is selected from the group  
20 consisting of 14-epi-LXB<sub>4</sub>, 15-epi-LXB<sub>4</sub> and 15-epi-LXB<sub>4</sub>-acetylenic.
17. A method to facilitate cardiac revascularization in a subject comprising the step of administering to the subject in need thereof, an effective amount of an LXB<sub>4</sub> compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that cardiac revascularization in the subject is facilitated.
- 25 18. The method of claim 17, wherein the LXB<sub>4</sub> compound is selected from the group consisting of 14-epi-LXB<sub>4</sub>, 15-epi-LXB<sub>4</sub> and 15-epi-LXB<sub>4</sub>-acetylenic